AUA: Genomic Urine Test Accurately Predicts Bladder Cancer
MONDAY, May 15, 2023 (HealthDay News) – A new genomic urine test can predict bladder cancer as many as 12 years before clinical signs and symptoms emerge, according to a study presented at the annual meeting of the American Urological Association, hel…
Learn MoreUrothelial Cancer Prediction Model Has High Sensitivity, Specificity
TUESDAY, March 21, 2023 (HealthDay News) — A urothelial cancer (UC) prediction model, which considers 10 genes with the highest performance from the UroAmp urinary comprehensive genomic profiling (uCGP) test, has high sensitivity and specificity, acc…
Learn MoreGemcitabine, Docetaxel a Viable Alternative to BCG in Bladder Cancer
MONDAY, March 13, 2023 (HealthDay News) — For patients with non-muscle invasive bladder cancer (NMIBC), gemcitabine and docetaxel therapy is associated with less high-grade disease recurrence, according to a study published online Feb. 28 in JAMA Net…
Learn MoreTrends in Genitourinary Cancers Examined in the United States
WEDNESDAY, Dec. 21, 2022 (HealthDay News) — The highest incidence rates of bladder cancer are seen in the Northeast, while the West has the highest deaths rates for prostate cancer among non-Hispanic White men, according to a study published online D…
Learn MoreLa FDA aprueba una terapia genética para el cáncer de vejiga difícil de tratar
LUNES, 19 de diciembre de 2022 (HealthDay News) — Los pacientes con un cáncer de vejiga de alto riesgo cuentan ahora con una nueva opción para tratarlo.El viernes, la Administración de Alimentos y Medicamentos (FDA) de EE. UU. aprobó una terapia gené…
Learn MoreFDA Approves Gene Therapy for Tough-to-Treat Bladder Cancer
MONDAY, Dec. 19, 2022 (HealthDay News) — The U.S. Food and Drug Administration on Friday approved a gene therapy called Adstiladrin (nadofaragene firadenovec-vncg), which is designed to work for patients with high-risk non-muscle-invasive bladder can…
Learn MoreFDA Approves Gene Therapy for Tough-to-Treat Bladder Cancer
MONDAY, Dec. 19, 2022 (HealthDay News) — Patients with a high-risk bladder cancer now have a new option to treat it.The U.S. Food and Drug Administration on Friday approved a gene therapy called Adstiladrin, which is designed to work for patients who…
Learn MoreSmoking Duration, Intensity Tied to Bladder Cancer Recurrence
FRIDAY, Dec. 9, 2022 (HealthDay News) — Longer duration and more pack-years of cigarette smoking are associated with a higher risk for recurrence of non-muscle-invasive bladder cancer (NMIBC), according to a study published online Nov. 30 in JAMA Net…
Learn MoreNab-Paclitaxel, Pembrolizumab Combo Active in Advanced Urothelial Cancer
THURSDAY, Nov. 10, 2022 (HealthDay News) — For patients with platinum-refractory or cisplatin-ineligible advanced urothelial cancer, the combination of nab-paclitaxel and pembrolizumab is promising, according to a study published online Nov. 1 in The…
Learn MorePatients Favor Single-Port Robotic System for Uro-Oncology Surgery
MONDAY, Oct. 31, 2022 (HealthDay News) — For patients undergoing urologic oncology procedures, use of the da Vinci single-port (SP) robotic system is perceived favorably by patients compared with a multiport platform, according to a study published i…
Learn More